Dinitro Cresol

Dinitro Cresol

SCHEMBL892354

Cc1cc([N+](=O)[O-])cc([N+](=O)[O-])c1O.Oc1ccccc1

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.78
GPR35 Q9HC97 6/20 0.78
MAPT P10636 5/20 0.53
HPGD P15428 4/20 0.53
KDM4E B2RXH2 4/20 0.53
TDP1 Q9NUW8 4/20 0.53
ALOX15 P16050 3/20 0.53
HSD17B10 Q99714 3/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
ALOX12 P18054 2/20 0.53
MAPK1 P28482 2/20 0.53
TTR P02766 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
RECQL P46063 1/20 0.53
PMP22 Q01453 1/20 0.53
HIF1A Q16665 1/20 0.53
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dinitro Cresol SCHEMBL1716451 0.92 GPR35 (0.93) ALDH1A1GPR35MAPTHPGDKDM4E
Dinitro Cresol SCHEMBL9005468 0.91 GPR35 (0.78) ALDH1A1GPR35MAPTHPGDKDM4E
Dinitro Cresol SCHEMBL1509581 0.91 GPR35 (0.78) ALDH1A1GPR35MAPTHPGDKDM4E
Dinitro Cresol SCHEMBL3976321 0.91 GPR35 (0.78) ALDH1A1GPR35MAPTHPGDKDM4E
Dinitro Cresol SCHEMBL2549698 0.90 GPR35 (0.89) ALDH1A1GPR35MAPTHPGDKDM4E
Dinitro Cresol SCHEMBL6859521 0.90 GPR35 (0.96) ALDH1A1GPR35MAPTHPGDKDM4E
Dinitro Cresol SCHEMBL9221013 0.89 ALDH1A1 (0.81) ALDH1A1GPR35MAPTHPGDKDM4E
Dinitro Cresol SCHEMBL4735684 0.89 GPR35 (0.81) ALDH1A1GPR35MAPTHPGDKDM4E
Trinitrophenol SCHEMBL27538937 0.89 CRHBP (0.62) ALDH1A1GPR35MAPTHPGDKDM4E
Dinitro Cresol SCHEMBL29430312 0.88 GPR35 (1.00) ALDH1A1GPR35MAPTHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107106683-A Molecular construct comprising targeting and effector components 中央研究院 2017-08-29 CN claimed
US-20110280890-A1 PRODRUGS OF CC-1065 ANALOGS IMMUNOGEN, INC. (US) 2011-11-17 US claimed
US-8012978-B2 Prodrugs of CC-A1065 analogs IMMUNOGEN, INC. (US) 2011-09-06 US claimed
WO-2009085576-A2 POSITIVE CONTROL CELL PELLETS FOR IMMUNOHISTOCHEMISTRY AND METHODS OF USE THEREOF SPRING BIOSCIENCE CORPORATION (US) 2009-07-09 WO claimed
WO-2009085573-A2 QUALITY CONTROL CELL DEVICE FOR IMMUNOHISTOCHEMISTRY ASSAY AND METHODS OF USE THEREOF SPRING BIOSCIENCE CORPORATION (US) 2009-07-09 WO claimed
US-20090028821-A1 PRODRUGS OF CC-A1065 ANALOGS SANOFI-AVENTIS (FR) 2009-01-29 US claimed
EP-1993999-A1 IMPROVED PRODRUGS OF CC-1065 ANALOGS Sanofi-Aventis (FR) 2008-11-26 EP claimed
WO-2007102069-A1 IMPROVED PRODRUGS OF CC-1065 ANALOGS SANOFI-AVENTIS (FR) 2007-09-13 WO claimed
EP-1832577-A1 Improved prodrugs of CC-1065 analogs Sanofi-Aventis (FR) 2007-09-12 EP claimed
US-4893614-A Apparatus for disintegrating a calculus by an underwater shock wave from outside the human body YACHIYODA SANGYO CO. LTD. (JP) 1990-01-16 US claimed
US-4322466-A Sheet printed with invisible inks LOCKLEY SERVICES PTY. LTD. (AU) 1982-03-30 US claimed
CN-111278449-B Method for treating and/or preventing graft versus host disease and/or diffuse alveolar hemorrhage and/or venous occlusive disease associated with hematopoietic stem cell transplantation 奥默罗斯公司 2025-01-07 CN disclosed
CN-118634322-A Methods for treating and/or preventing venous occlusive disease 奥默罗斯公司 2024-09-13 CN disclosed
CN-115594555-A Environment-friendly high-temperature-resistant ignition agent 西安庆华民用爆破器材股份有限公司(CN) 2023-01-13 CN disclosed
US-11542224-B2 Synthesis of and compositions containing diaminoacetals and diaminoketals ADITYA BIRLA CHEMICALS (USA), INC. (US) 2023-01-03 US disclosed
US-4477593-A Sheet printed with invisible inks, developers and erasure compounds _for invisible inks LOCKLEY SERVICES PTY. LTD. (AU) 1984-10-16 US disclosed
US-4347148-A Full and lubricant compositions containing nitro phenols THE LUBRIZOL CORPORATION (US) 1982-08-31 US disclosed
US-4322466-A Sheet printed with invisible inks LOCKLEY SERVICES PTY. LTD. (AU) 1982-03-30 US disclosed
US-4231757-A OIL ADDITIVES; DETERGENTS; ANTISLUDGE AGENTS THE LUBRIZOL CORPORATION (US) 1980-11-04 US disclosed
US-4197198-A Treatment of nitrated phenol containing effluent streams COSDEN TECHNOLOGY, INC. (US) 1980-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110280890-A1 PRODRUGS OF CC-1065 ANALOGS CASP5, SENP5, CWC15 ALDH1A1 2278/4885GPR35 844/4885MAPT 4463/4885
US-11542224-B2 Synthesis of and compositions containing diaminoacetals and diaminoketals SRM, AOC1, SAT1 ALDH1A1 914/4885GPR35 3109/4885MAPT 648/4885
US-20090028821-A1 PRODRUGS OF CC-A1065 ANALOGS PDIA5, CA6, STS ALDH1A1 971/4885GPR35 1846/4885MAPT 4480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.